PURPOSE: Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. MATERIALS AND METHODS: The medical records of anthracycline- and taxane-pretreated metastatic breast cancer patients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m(2)) and vinorelbine (25 mg/m(2)) were administered intravenously on days 1 and 8 every 3 weeks. RESULTS: Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1 approximately 5). The overall response rate was 30% (95% CI, 18.1 approximately 41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of the patients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracycline- and/or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable. CONCLUSION: Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.
PURPOSE:Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. MATERIALS AND METHODS: The medical records of anthracycline- and taxane-pretreated metastatic breast cancerpatients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m(2)) and vinorelbine (25 mg/m(2)) were administered intravenously on days 1 and 8 every 3 weeks. RESULTS: Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1 approximately 5). The overall response rate was 30% (95% CI, 18.1 approximately 41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of the patients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracycline- and/or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable. CONCLUSION:Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.
Entities:
Keywords:
Anthracycline; Breast neoplasms; Gemcitabine; Taxane; Vinorelbine
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Emanuela Rossi; Francesco Perrone; Vincenzo Labonia; Gabriella Landi; Francesco Nuzzo; Gerardo Amabile; Cesare Gridelli; Massimo Di Maio; Giuseppe D'Aiuto; Andrea de Matteis Journal: Oncology Date: 2003 Impact factor: 2.935
Authors: G Mariani; P Tagliabue; P Zucchinelli; C Brambilla; R Demicheli; E Villa; A Marchianò; P Valagussa; G Bonadonna; L Gianni Journal: Breast Cancer Res Treat Date: 2001-12 Impact factor: 4.872
Authors: C Nicolaides; M A Dimopoulos; E Samantas; D Bafaloukos; C Kalofonos; G Fountzilas; E Razi; P Kosmidis; N Pavlidis Journal: Ann Oncol Date: 2000-07 Impact factor: 32.976
Authors: R S Herbst; C Lynch; M Vasconcelles; B A Teicher; G Strauss; A Elias; I Anderson; P Zacarola; N H Dang; T Leong; R Salgia; A T Skarin Journal: Cancer Chemother Pharmacol Date: 2001-08 Impact factor: 3.333
Authors: C F Verschraegen; T Sittisomwong; A P Kudelka; E d Guedes; M Steger; T Nelson-Taylor; M Vincent; R Rogers; E N Atkinson; J J Kavanagh Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Pamela Abdayem; Marwan Ghosn; Vicente Valero; Ronald Walters; Banu Arun; James L Murray; Richard Theriault; Debbie Frye; Nuhad K Ibrahim Journal: J Cancer Date: 2014-03-29 Impact factor: 4.207